AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02720432 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HABIT
Description: hand-arm bimanual intensive training
Study NCT02720432 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: baby-massage
Description: instructions for baby-massage
Study NCT03774849 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PicoWay™ 532nm fractional handpiece
Description: PicoWay™ Laser System is picosecond 532/1064/785 laser
Study NCT03774849 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PicoWay™ 730nm wavelength
Description: PicoWay™ Laser System is picosecond 532/1064/785 laser
Study NCT03774849 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PicoWay™ 1064nm fractional handpiece
Description: PicoWay™ Laser System is picosecond 532/1064/785 laser
Study NCT05249153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: low dose of dexmedetomidine with sufentanil
Description: low dose of dexmedetomidine in PCIA (0.05ug/kg/h sufentanil with 0.05ug/kg/h dexmedetomidine infusion, 0.05ug/kg sufentanil with 0.05ug/kg dexmedetomidine bolus)
Study NCT05249153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: high dose of dexmedetomidine with sufentanil
Description: high dose of dexmedetomidine in PCIA (0.05ug/kg/h sufentanil with 0.1ug/kg/h dexmedetomidine infusion, 0.05ug/kg sufentanil with 0.1ug/kg dexmedetomidine bolus)
Study NCT03981887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nafithromycin
Description: Nafithromycin 200 mg as IV infusion
Study NCT03981887 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo administered as IV infusion
Study NCT02704702 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Fimasartan
Study NCT02704702 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Rosuvastatin
Study NCT02704702 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Fimasartan + Rosuvastatin
Study NCT02885740 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quantification assay of adenosine and methionine cycle metabolites
Study NCT02885740 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quantification assay of adenosine and methionine cycle metabolites
Study NCT02885740 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Polymorphism analysis of genes related to adenosine metabolism and methionine cycle
Study NCT02885740 — intervention group
Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: Polymorphism analysis of genes related to adenosine metabolism and methionine cycle
Study NCT02885740 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quantitative and qualitative nutritional evaluation
Description: Questionnaire on consumption of 208 foods and drinks
Study NCT02885740 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quantitative and qualitative nutritional evaluation
Description: Questionnaire on consumption of 208 foods and drinks
Study NCT02885740 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sample
Study NCT02885740 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Blood sample
Study NCT00167141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: injection of hormonal male contraceptive
Description: testosterone injections 4 times
Study NCT04120753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OLOMAX 20/5/5mg
Description: Tablets, Oral, QD
Study NCT04120753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OLOMAX 20/5/10mg
Description: Tablets, Oral, QD
Study NCT04120753 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olmesartan 20 mg/Amlodipine 5 mg
Description: Tablets, Oral, QD
Study NCT02743949 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vonoprazan
Description: Vonoprazan over-encapsulated capsules
Study NCT02743949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vonoprazan
Description: Vonoprazan over-encapsulated capsules
Study NCT02743949 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole
Description: Esomeprazole over-encapsulated tablets
Study NCT02743949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: Esomeprazole over-encapsulated tablets
Study NCT02743949 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole Placebo
Description: Esomeprazole placebo-matching capsules
Study NCT02743949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole Placebo
Description: Esomeprazole placebo-matching capsules
Study NCT03389555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vitamin C, vitamin B1, hydrocortisone
Description: Vitamin C (1.5g) plus vitamin B1 (100mg) will be diluted in 100ml 0.9% NACL(normal saline) and administered IV every 6 hours for 4 days or until participant is discharged from the ICU. Hydrocortisone 50mg/ml will be administered via IV push over 1-2 minutes every 6hours for 4 days or until the patient is discharged from the ICU.
Study NCT03389555 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline (0.9% NaCl solution) volume to match all components
Study NCT03806556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: IV medication administered after patient meets inclusion/exclusion criteria
Study NCT03806556 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: IV medication administered after patient meets inclusion/exclusion criteria
Study NCT03109093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Patients will receive blinatumomab at a dose of 28 µg/day as continuous intravenous infusion at constant flow rate for four weeks, followed by a two-week infusion free interval, defined as one treatment cycle. Up to of four cycles will be performed.~In case of defined toxicities, the dose of blinatumomab may be reduced to 9µg/day.~Patients with an MRD relapse may qualify to receive additional treatment with blinatumomab.
Study NCT02483728 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Patch Test
Description: Patch testing is a technique used to diagnose an allergic skin disease called allergic contact dermatitis. It attempts to reproduce in small scale allergic reactions of the skin from things that come in contact with it.This is the standard of care to determine allergic contact dermatitis.
Study NCT04723745 — intervention group
Intervention type: BEHAVIORAL
Intervention: V-TRACTS Assessment/Feedback
Description: The proposed V-TRACTS assessment strategically targets emotional, cognitive and behavioral functions that we have determined are highly predictive of long-term outcome in Veterans. The assessment targets domains of head injury, psychological trauma, depression, suicidality, anxiety, chronic pain and sleep, substance use and activity level. This assessment will, in most cases, be completed online using the Qualtrics platform and online using telehealth or other approved platform for the clinical interview. Once the assessment is complete, the clinical team will convene a consensus meeting to review the case and determine a course of recommended additional assessment and/or rehabilitation action. After a consensus is reached, a V-TRACTS psychologist/supervised fellow will provide comprehensive feedback encompassing the entire assessment battery and offer rehabilitation options that would be targeted to the individual veteran's needs via VA telehealth or other approved online service.
Study NCT04723745 — intervention group
Intervention type: BEHAVIORAL
Intervention: OPTIONAL Brief Assessment of Thinking
Description: A neuropsychological/cognitive assessment will be conducted to gather information about functioning in the areas of memory, attention, and thinking. This assessment is designed to be done online in a single session, and it will take approximately 45-90 minutes to complete. The test battery is designed to focus on the specific cognitive abilities thought to be impacted by blast, mTBI, PTSD, etc. This battery is not intended to be an exhaustive assessment of all neuropsychological functions.
Study NCT04723745 — intervention group
Intervention type: BEHAVIORAL
Intervention: OPTIONAL STEP-Home-Brief
Description: STEP-Home-Brief is a condensed version of the 12-week experimental program STEP-Home that will target four core skills (problem solving, emotional regulation, attention training, and health and wellness). It will be individualized to Veterans' problems: vocation/career, community reintegration, psychoeducation to destigmatize barriers to mental health, substance misuse, anger management, and family and intimate partner relationships. STEP-Home-Brief will include 1-3 sessions using the same treatment modules as the 12-week program in a condensed, targeted format.
Study NCT04723745 — intervention group
Intervention type: BEHAVIORAL
Intervention: OPTIONAL At-home Exercise Program
Description: This is a 5-week, full-body exercise program that can be done in the convenience of the Veteran's home, using only bodyweight as resistance and with household items as equipment. Given the online delivery of this program, they will receive access to instructional videos and materials that demonstrate how to perform each exercise safely and correctly. Participants will be contacted by study staff weekly over the phone to maintain interest and monitor adherence during the study.
Study NCT04723745 — intervention group
Intervention type: BEHAVIORAL
Intervention: OPTIONAL Referral to 12-week STEP-Home
Description: Referral to the experimental 12-week STEP-Home workshop research study (VABHS IRB #3210).
Study NCT04723745 — intervention group
Intervention type: BEHAVIORAL
Intervention: OPTIONAL Clinical Referral
Description: Clinical referrals to VABHS clinical services based on assessment and patient-directed primary problem/complaint.
Study NCT00638378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Ruxolitinib 25 mg tablets taken with water twice a day.
Study NCT00793403 — intervention group
Intervention type: OTHER
Intervention: As per routinary clinical care
Description: As per routine clinical care
Study NCT02957877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nadroparin
Description: A nadroparin infusion regimen (loading dose of 35 IU/kg, followed by 10 IU/kg per hour for 6 hours) is administered as anticoagulation during the 8-hour hemodialysis.
Study NCT02957877 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Unfractionated heparin
Description: The individualized unfractionated heparin infusion regimen currently employed by the recruited patients in their home dialysis treatment is administered as anticoagulation during the 8-hour hemodialysis.
Study NCT03024450 — intervention group
Intervention type: DRUG
Intervention: H+CT
Description: All patients were treated with trastuzumab plus chemotherapy as the first-line therapy. There were no protocol-specified chemotherapy regimens. This is a prospective observational study. Efficacy and safety of trastuzumab were analyzed, clinical and pathological data were collected to evaluate the potential prognostic factors on progressive free survival.
Study NCT01265732 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PF-04191834
Description: single dose, 100mg, dispersion
Study NCT01265732 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PF-04191834
Description: single dose, 100mg, suspension
Study NCT01265732 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PF-04191834
Description: single dose, 300mg, suspension
Study NCT04405986 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Auditory Evoked Potentials (AEP)
Description: Record of electrophysiological responses (Auditory Evoked Potentials or AEP) during auditory stimulations with an electroencephalogram (EEG).
Study NCT04405986 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blink and Masseter Inhibitory Reflex
Description: Electrophysiological exploration while stimulating trigeminal nerve to record 1) motor response induced (muscle contraction delay (Blink)) of the facial nerve, or 2) the contraction inhibition of masseters (Masseter Inhibitory Reflex (MIR)).
Study NCT01616524 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegylated interferon lambda (pegIFNλ)
Description: Syringe, Subcutaneous, 180 μg, Once weekly, 24 weeks
Study NCT01616524 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegylated interferon lambda (pegIFNλ)
Description: Syringe, Subcutaneous, 180 μg, Once weekly, 12 weeks
Study NCT03201926 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: mealworms
Description: 10g , 3 times a day , po, 2 months
Study NCT03201926 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: grain powder
Description: grain powder, 10g ,3times one day,2months
Study NCT03720041 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: R1: Ixazomib, Lenalidomide, Dexamethasone (IRD) induction therapy - reactive arm
Description: In the reactive arm at Randomisation 1, participants will receive IRD induction therapy with standard up-front dosing, with toxicity assessed at each cycle and doses adjusted in accordance with the guidelines given in the trial protocol. All participants will be given the following starting doses:~Ixazomib: 4mg/day on days 1, 8 and 15, taken orally~Lenalidomide: 25mg/day on days 1-21, taken orally~Dexamethasone: 40mg on days 1, 8, 15 and 22 for participants aged ≤75 years, or 20mg on days 1, 8, 15 and 22 for participants aged > 75 years; taken orally~Participants will receive this dosing regimen for 12 cycles of induction treatment, in the absence of disease progression or unacceptable toxicity. Each cycle is 28 days.
Study NCT03720041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R1: Ixazomib, Lenalidomide, Dexamethasone (IRD) induction therapy - adaptive arm
Description: In the adaptive arm at Randomisation 1, participants will receive IRD induction therapy with up-front dose reductions adjusted according to their frailty score: fit, unfit, or frail. The starting doses for each frailty category are described below:~1. Fit category:~   Ixazomib: 4mg/day on days 1, 8 and 15, taken orally Lenalidomide: 25mg on days 1-21, taken orally Dexamethasone: 40mg on days 1, 8, 15 and 22, taken orally~2. Unfit category:~   Ixazomib: 4mg/day on days 1, 8 and 15, taken orally Lenalidomide: 15mg on days 1-21, taken orally Dexamethasone: 20mg on days 1, 8, 15 and 22, taken orally~3. Frail category:~Ixazomib: 4mg/day on days 1, 8 and 15, taken orally Lenalidomide: 10mg on days 1-21, taken orally Dexamethasone: 10mg on days 1, 8, 15 and 22, taken orally~Participants will receive this dosing regimen for 12 cycles of induction treatment, in the absence of disease progression or unacceptable toxicity. Each cycle is 28 days.
Study NCT03720041 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: R2: Lenalidomide plus placebo maintenance
Description: Participants randomised to receive lenalidomide plus placebo maintenance at Randomisation 2 will receive the following starting doses:~Lenalidomide: 10mg\*/day on days 1-21, taken orally Placebo: 4mg\*/day on days 1, 8 and 15~\* or final dose administered at the end of induction treatment if lower.~This dosing regimen is continued for every maintenance cycle. Participants will continue maintenance treatment until disease progression or intolerance/unacceptable toxicity. Each maintenance cycle is 28 days.~Randomisation 2 is double-blind - participants and their treating clinicians will be blinded to maintenance allocation.
Study NCT03720041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R2: Lenalidomide + ixazomib maintenance
Description: Participants randomised to receive lenalidomide plus ixazomib maintenance at Randomisation 2 will receive the following starting doses:~Lenalidomide: 10mg\*/day on days 1-21, taken orally Ixazomib: 4mg\*/day on days 1, 8 and 15~\* or final dose administered at the end of induction treatment if lower.~This dosing regimen is continued for every maintenance cycle. Participants will continue maintenance treatment until disease progression or intolerance/unacceptable toxicity. Each maintenance cycle is 28 days.~Randomisation 2 is double-blind - participants and their treating clinicians will be blinded to maintenance allocation.
Study NCT02253563 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance Training
Study NCT02253563 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Balance Training
Study NCT02352454 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aurix
Description: Aurix is a platelet-rich plasma gel used in the treatment of non-healing wounds. It will be administered twice weekly for 2 weeks then weekly.
Study NCT05210517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 MG
Description: 25 once daily one week treatment
Study NCT05210517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benzbromaron
Description: 100 mg once daily 1 one week treatment
Study NCT05210517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 MG + benzbromarone 100 mg
Description: combined treatment once daily for one week
Study NCT00592163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZIO-101-C (Darinaparsin)
Description: Dose Escalation study, 200 mg - 900 mg, cumulative daily dose split to be taken BID 7 times a week (>8 hours between doses) for 3 weeks followed by 1 week of rest
Study NCT05027126 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexketoprofen 25 MG
Description: Pharmaceutical Form: Tablets Dosage: 25 mg Adminstration way: Oral
Study NCT05027126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fixed dose Dexketoprofen-Vitamin B Complex
Description: Pharmaceutical Form: capsule Dosage: 25 mg of Dexketoprofen + Cyanocobalamin 500 µg, Thiamine 100 mg, Pyridoxine 50 mg. Administration way: oral
Study NCT01320319 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule form, 960 mg to be taken three times a day.
Study NCT01320319 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Experimental: Nutritional Supplementation with EPA
Description: Capsule form, EPA, 960mg to be taken three times a day.
Study NCT04545190 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Glucose
Description: To investigate the effects of glucose intake during resistance training on muscle biological adaptations
Study NCT04545190 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Glucose
Description: To investigate the effects of glucose intake during resistance training on muscle biological adaptations
Study NCT03558334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transplantation of mesenchymal stem cell
Description: Human umbilical cord-derived mesenchymal stem cell will be given to preterm infants through intravenous infusion.~Dose A - 1 million cells per kg Dose B - 5 million cells per kg
Study NCT03558334 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: No transplantation of mesenchymal stem cell
Description: Human umbilical cord-derived mesenchymal stem cell will be not given to preterm infants through intravenous infusion.
Study NCT03010137 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Incisional Negative Pressure Wound Therapy
Study NCT03010137 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Standard Closure with Skin Glue
Study NCT03010137 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PICO (Smith&Nephew)
Description: Off the shelf, disposable negative pressure wound therapy device. Contains sterile dressing as well as an attached small (pager sized) suction device/canister.
Study NCT03010137 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Dermabond
Description: Final wound closure with skin glue.
Study NCT00322023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-serine
Description: D-serine at following dose levels: 30 mg/kg, 60 mg/kg, and 120 mg/kg. PK/PD studies done at day 1. Medication will be administered as powder dissolved in liquid given in two divided doses daily for 4 weeks.
Study NCT00322023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-serine
Study NCT03336801 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Back Surgery
Description: All patients undergo basic back surgery.
Study NCT03336801 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Anesthesia on propofol alone.
Study NCT03336801 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: Anesthesia on sevoflurane alone.
Study NCT00369174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rosiglitazone maleate
Description: Given orally
Study NCT01616524 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegylated interferon alfa-2a (pegIFNα-2a)
Description: Syringe, Subcutaneous, 180 μg, Once weekly, 24 weeks
Study NCT01616524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Tablets, Oral, 400 mg, Twice daily, 24 weeks
Study NCT01616524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Tablets, Oral, 400 mg, Twice daily, 12 weeks
Study NCT01616524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir
Description: Tablets, Oral, 60 mg, Once daily, 12 weeks
Study NCT01616524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching Daclatasvir
Description: Tablets, Oral, 0 mg, Once daily, 12 weeks
Study NCT02597894 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Biopsy of Prostate
Description: Undergo biopsy
Study NCT02597894 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies